UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major cancer trial tests if adding third drug helps fight tough bile duct cancers
Disease control CompletedThis large, completed Phase 3 trial tested whether adding a third chemotherapy drug (nab-paclitaxel) to the standard two-drug treatment (gemcitabine and cisplatin) works better for people newly diagnosed with advanced cancers of the bile ducts, gallbladder, or liver. The study in…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Hopeful combo tested for tough liver cancer
Disease control CompletedThis study tested whether adding two immunotherapy drugs (durvalumab and SNDX-6532) after a standard liver-directed treatment could help control a hard-to-treat liver cancer. It involved 5 patients whose cancer could not be surgically removed. The main goals were to see if the tr…
Matched conditions: UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC